CANF (Can Fite Biopharma) Moat Score: 2/10 (As of Jun. 27, 2026)


CANF Can Fite Biopharma Ltd CANF
55 GF Score
Price $2.75
GF Value $5.68
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Can Fite Biopharma Moat Score?

Can Fite Biopharma CANF -6.46% 55 Moat Score is 2 as of Jun. 27, 2026. GuruFocus rates CANF with a GF Score™ of 55/100 and a GF Value™ of $5.68 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,404 Biotechnology companies, Can Fite Biopharma ranks better than 58.12% on this metric.

Can Fite Biopharma has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Can Fite Biopharma has No Moat: Can Fite Biopharma Ltd lacks significant market leadership or proprietary technology. The company operates in a highly competitive biotech sector with minimal customer switching costs and limited brand strength. Its intellectual property and R&D capabilities are not sufficient to establish a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Can Fite Biopharma might have No Moat - Very weak/transient advantages.

Can Fite Biopharma  (AMEX:CANF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Can Fite Biopharma Moat Score Related Terms

CANF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Can Fite Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biopharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Can Fite Biopharma's Moat Score falls into.


CANF
55GF Score
Can Fite Biopharma Ltd CANF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Can Fite Biopharma (CANF) has a Moat Score of 2 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Can Fite Biopharma ranks #588 out of 1404 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Can Fite Biopharma's Moat Score too high?
Can Fite Biopharma's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Can Fite Biopharma's value of 2 is 0% at this industry median. Based on the distribution chart, Can Fite Biopharma ranks #588 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #588 out of 1404 companies for Moat Score. This puts Can Fite Biopharma in the upper half of its industry. The industry median Moat Score is 2.00. Can Fite Biopharma's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.68, compared to a current price of $2.75 — trading 51.6% below its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Moat Score is 2 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Can Fite Biopharma (CANF) Overvalued in 2026?

Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued. The current stock price of $2.75 is trading 51.6% below its estimated GF Value™ of $5.68. GuruFocus considers Can Fite Biopharma to be Possible Value Trap.

Key valuation signals for CANF:

  • Moat Score: 2
  • GF Value™: $5.68 vs. price of $2.75 (51.6% below fair value)
  • GF Score™: 55/100 with 4 warning signs
  • Industry Position: 0% at the Biotechnology median (#588 of 1404)

No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Can Fite Biopharma Business Description

Other Exchanges CANF:Israel
Address 26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score

Get the complete analysis for CANF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.75
Price
$5.68
GF Value